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MaManaging risk related to low-density lipoprotein (LDL) is vital in therapy for patients at risk for atherosclerotic cardio-
vascular disease (ASCVD) events given its important etiologic role in atherogenesis. Despite decades of research showing
reduction of ASCVD risk with multiple approaches to lowering of LDL cholesterol, there continue to be signiﬁcant gaps in
care with inadequate numbers of patients receiving standard of care lipid-lowering therapy. Confusion regarding
implementation of the multiple published clinical practice guidelines has been identiﬁed as one contributor to suboptimal
management of LDL-related risk. This review summarizes the current guidelines for reduction of LDL-related cardio-
vascular risk provided by a number of major professional societies, which have broad applicability to diverse populations
worldwide. Statements have varied in the process and methodology of development of recommendations, the grading
system for level and strength of evidence, the inclusion or exclusion of expert opinion, the suggested ASCVD risk
assessment tool, the lipoproteins recommended for risk assessment, and the lipoprotein targets of therapy. The simi-
larities and differences among important guidelines in the United States and internationally are discussed, with recom-
mendations for future strategies to improve consistency in approaches to LDL-related ASCVD risk and to reduce gaps in
implementation of evidence-based therapies. (J Am Coll Cardiol 2014;64:196–206) © 2014 by the American College of
Cardiology Foundation.L ow-density lipoprotein (LDL) plays a signiﬁ-cant role in the promotion, development,and progression of vascular atherosclerosis
through a pathway that involves endothelial cell
dysfunction, lipid oxidation and accumulation, foam
cell formation, and inﬂammatory responses (1).
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197of LDL-related cardiovascular risk, there are inade-
quate numbers of appropriate patients receiv-
ing standard of care lipid-lowering therapy (5,6).
Numerous factors may contribute to gaps in care
and confusion regarding implementation of appro-
priate guidelines for various patient populations
may play a contributory role in suboptimal patient
management.
In March 2013, the American College of Cardiology
(ACC) Executive Committee approved a 3-year, mul-
tistakeholder quality initiative program, LDL:
Address the Risk, to improve patient outcomes by
increasing awareness of gaps in lipid management
and the importance of managing LDL-related risk.
One component of this program, the LDL: Address the
Risk Think Tank, was convened on October 10, 2013,
at the ACC’s Heart House in Washington, DC. Partic-
ipants in this conference included representatives of
17 medical specialty societies and other experts in
cardiovascular disease risk reduction and lipidology.
The purpose of this review is to summarize concerns
regarding gaps in care related to implementation of
the plethora and sometimes discordant clinical prac-
tice guidelines for the management of LDL-related
risk, which were highlighted during the LDL:
Address the Risk Think Tank. The discussion evalu-
ates guidelines with broad applicability in large pop-
ulations worldwide. We also highlight similarities and
differences in the process and methodology for
formulation of recommendations, the inclusion/
exclusion of expert opinion and evidence from large
randomized controlled trials (RCTs) and meta-
analyses, the methodology for grading the strength
and level of evidence, the recommended algorithms
used for cardiovascular risk assessment, speciﬁc li-
poprotein targets of therapy, and consideration of
special patient populations.
GUIDELINES FOR THE MANAGEMENT OF
LDL-RELATED ASCVD RISK
NATIONAL CHOLESTEROL EDUCATION PROGRAM
ADULT TREATMENT PANEL. In 2001 and 2002, the
Third Report of the Expert Panel on Detection, Eval-
uation, and Treatment of High Blood Cholesterol in
Adults (Adult Treatment Panel [ATP] III) published
updated recommendations for cholesterol testing and
management (7,8) (Central Illustration). Each evi-
dence statement was presented with the category or
type of supporting evidence and the strength of the
evidence. The standard fasting lipid panel was
considered the preferred initial test. ATP III focused
on intensive treatment of patients with manifest
CHD, but also recognized the signiﬁcant CHD riskpresent in persons with multiple risk factors.
The Framingham risk assessment algorithm
for projection of 10-year absolute CHD risk
was recommended to identify patients with
multiple risk factors who would beneﬁt from
more intensive therapy (9) (Table 1). Diabetes
was reclassiﬁed as a CHD “risk equivalent,”
and patients with multiple metabolic risk
factors (metabolic syndrome) were identiﬁed
as candidates for intensiﬁed therapeutic
lifestyle changes. In the ATP III guidelines,
optimal LDL-C was identiﬁed as <100 mg/dl
and low high-density lipoprotein cholesterol
(HDL-C) was raised from <35 to <40 mg/dl. In
patients with triglyceride levels $200 mg/dl,
the calculation of non–HDL-C (total
cholesterol  HDL-C) was recommended for
consideration of treatment beyond LDL
lowering. Thus, LDL-C was considered the
primary target of therapy and non–HDL-C as a
secondary treatment goal in patients with
hypertriglyceridemia. The 2004 update of
ATP III (10) considered 5 major recent clinical
outcome trials published between 2001 and 2004,
which addressed issues not previously considered in
clinical trials of cholesterol lowering (11–15). These
trials supported the consideration of diabetes as a
high-risk category/CHD risk equivalent, the beneﬁt of
LDL-C lowering in older persons, an optional goal of
LDL-C #70 mg/dl in very high-risk patients, and
combination therapy with statin plus a ﬁbrate or
niacin in patients with triglycerides $200 mg/dl or
low HDL-C. The NCEP ATP III guidelines and 2004
update have served as the standard of care for at-risk
patients with hyperlipidemia for nearly a decade in
the United States.
INTERNATIONAL ATHEROSCLEROSIS SOCIETY.
The International Atherosclerosis Society (IAS) Posi-
tion Paper on Global Recommendations for the Man-
agement of Dyslipidemia was published online in July
2013, and recommendations were based on interna-
tional consensus among experts frommultiple regions
around the world (16). Given the strength of evidence
in secondary ASCVD prevention, priority was given to
RCTs to inform and guide recommendations in this
high-risk population. For primary prevention, a
limited number of RCTs and few multinational studies
were considered. Thus, the recommendations for
patients without manifest ASCVD were based on
epidemiologic, genetic, and basic research, as well
as available clinical trials. A discussion of the IAS
expert panel deliberations are reviewed for each
recommendation, which provides insight into
CENTRAL ILLUSTRATION Comparison of Clinical Guidelines for the Management of Risks Related to LDL in ASCVD
apoA1 ¼ apolipoprotein A1; apoB ¼ apolipoprotein B; ASCVD ¼ atherosclerotic cardiovascular disease; CAD ¼ coronary artery disease; CHD ¼
coronary heart disease; CKD ¼ chronic kidney disease; CV ¼ cardiovascular; eGFR ¼ estimated glomerular ﬁltration rate; HDL-C ¼ high-density
lipoprotein cholesterol; hs-CRP ¼ high-sensitivity C-reactive protein; LDL-C ¼ low-density lipoprotein cholesterol; LDL-P ¼ low-density
lipoprotein particle; TC ¼ total cholesterol; TG ¼ triglycerides.
Morris et al. J A C C V O L . 6 4 , N O . 2 , 2 0 1 4
Guidelines for Management of LDL-Related Risk J U L Y 1 5 , 2 0 1 4 : 1 9 6 – 2 0 6
198
J A C C V O L . 6 4 , N O . 2 , 2 0 1 4 Morris et al.
J U L Y 1 5 , 2 0 1 4 : 1 9 6 – 2 0 6 Guidelines for Management of LDL-Related Risk
199considerations of the type and strength of available
evidence evaluated. The goal of the IAS document is
to integrate existing guidelines and provide interna-
tional consensus guidelines with worldwide applica-
bility. The guideline assigns priority to assessment
of lifetime risk of total ASCVD morbidity and/or mor-
tality, rather than 10-year risk, as the authors
considered this to be the purpose of primary preven-
tion. Four long-term risk assessment tools are
reviewed for primary prevention (2 from Framing-
ham, the Cardiovascular Lifetime Risk Pooling Proj-
ect, and QRISK [17–21]), and recommendations are
made for appropriate selection or recalibration of risk
algorithms for speciﬁc ethnic populations. The IAS
favors non–HDL-C as the major target of lipid-
lowering therapy, as these experts consider it to be
more reﬂective of atherogenicity in the presence of
elevated triglycerides. Also, non–HDL-C can be
measured in the nonfasting state. LDL-C is considered
an alternate target of treatment. The IAS deﬁnes
“optimal levels” of atherogenic lipoproteins in pri-
mary and secondary prevention, which are identical
to those of ATP III, but does not provide speciﬁc
treatment goals. Finally, the society recommends that
the intensity of therapy be adjusted to the patient’s
long-term ASCVD risk, and the potency of therapy be
based on the provider’s clinical judgment.
EUROPEAN SOCIETY OF CARDIOLOGY/EUROPEAN
ATHEROSCLEROSIS SOCIETY. The European Society
of Cardiology (ESC)/European Atherosclerosis Society
(EAS) Guidelines for the Management of Dyslipidae-
mias, published in 2011, present comprehensive rec-
ommendations for lipid-lowering therapy in primary
and secondary prevention in the general European
population, as well as special and regional pop-
ulations (22). Following a systematic review of
the literature, each proposed recommendation in-
cludes a description of the class of evidence and the
level of evidence. Similar to NCEP ATP III and IAS,
the ESC/EAS guidelines recommend that the intensity
of lipid therapy be adjusted to the level of risk.
However, estimation of 10-year total fatal ASCVD risk
(ﬁrst fatal atherosclerotic event, heart attack, stroke,
or other occlusive arterial disease, including sudden
cardiac death) by the SCORE (Systematic Coronary
Risk Estimation) system is recommended as the
preferred risk assessment algorithm (23). Low- and
high-risk charts are provided for adjustment of risk
assessments in speciﬁc countries in Europe. The
initial patient evaluation should include a full lipid
panel, as well as a non–HDL-C and triglyceride/HDL-C
ratio. Apolipoprotein B (Apo B) or Apo B/Apo A1 may
be considered as alternate risk markers. LDL-C is
recommended as the primary target of therapy. Inagreement with the NCEP ATP III update, for patients
at very high risk (established ASCVD, diabetes,
chronic kidney disease (CKD), or 10-year total ASCVD
risk of $10% by SCORE), the target LDL-C level
is <70 mg/dl or $50% reduction when target level
cannot be reached. For patients at high ASCVD risk
(markedly elevated single ASCVD risk factor or
SCORE $5 to <10%) an LDL-C goal of <100 mg/dl is
suggested. In patients with the metabolic syndrome,
diabetes, or CKD with combined dyslipidemias, the
ESC/EAS guidelines suggest that non–HDL-C or Apo B
may be measured and considered as a secondary
target of therapy, similar to recommendations of the
NCEP ATP III update for assessment of non–HDL-C.
More recent publications including the updated
European Guidelines on Cardiovascular Disease Pre-
vention in Clinical Practice (version 2012) (24), the
2013 ESC Guidelines on the Management of Stable
Coronary Artery Disease (25), and the ESC Guidelines
on Diabetes, Pre-Diabetes, and Cardiovascular Dis-
eases in collaboration with the European Association
for the Study of Diabetes (26) all have subsequently
supported these earlier recommendations of the ESC/
EAS Dyslipidaemia Management Guidelines.
CANADIAN CARDIOVASCULAR SOCIETY. The Cana-
dian Cardiovascular Society (CCS) updated its Guide-
lines for the Diagnosis and Treatment of Dyslipidemia
for the Prevention of Cardiovascular Disease in the
Adult in 2012 (27). The GRADE (Grading of Recom-
mendations Assessment, Development, and Evalu-
ation) system (28) was used as the standard for
consideration of scientiﬁc evidence (strength and
quality of evidence). In agreement with the NCEP
ATP III, IAS, and ESC/EAS guidelines, the CCS
suggests that the intensity of treatment be modu-
lated by the level of ASCVD risk. The recommen-
ded risk assessment algorithm is the Framingham
Risk Score (FRS) to estimate the 10-year risk of
total ASCVD events (29). If a family history of pre-
mature ASCVD among ﬁrst-degree relatives is pre-
sent, the FRS risk estimate is doubled and is
referred to as the modiﬁed FRS. LDL-C remains the
primary treatment target, with an optimal LDL-C
level of #2.0 mmol/l or approximately 77 mg/dl.
Non–HDL-C and Apo B are considered to have a
strong recommendation and high-quality evidence
as alternative treatment targets for optimal risk
reduction (non–HDL-C #2.6 mmol/l, Apo B #80
mg/dl). Secondary testing is considered of possible
beneﬁt in intermediate-risk patients with FRS
5% to 19% and may include lipoprotein(a), high-
sensitivity C-reactive protein (hs-CRP), coronary
calcium scoring, ankle brachial index, or other
noninvasive measurements.
TABLE 1 Comparison of ASCVD Risk Assessment Tools
Source
Recommended Risk
Assessment Tool
Forecast
Capability of
Tool (yrs)
Risk Factors Included
for Risk Estimation
Atherosclerotic
Cardiovascular Disease
Outcome Predicted
Population Used
for Derivation/Validation
of Risk Algorithm
National Cholesterol
Education Program
Adult Treatment
Panel III (7,8)
Original Framingham
Risk Score (9)
10 Sex, age, TC, HDL-C,
blood pressure, diabetes,
smoking status
Myocardial infarction and
coronary heart disease
death
 Framingham original and
offspring cohorts
 Men, n ¼ 2,489
 Women, n ¼ 2,856
 Ages 3074 yrs
 Caucasian
International Atherosclerosis
Society (16)
Updated Framingham
Risk Score (17) with
recalibration coefﬁcients
for different patient
populations
Lifetime Risk factor status age 50 yrs:
TC, systolic blood
pressure, diastolic blood
pressure, smoking
status, diabetes
Myocardial infarction,
coronary insufﬁciency,
angina, stroke,
claudication, CVD death
based on measured risk
factors at age 50 yrs
 Framingham original and
offspring cohorts
 Men, n ¼ 3,564
 Women, n ¼ 4,362
 Ages 3074 yrs
 Caucasian
European Society of
Cardiology/European
Atherosclerosis
Society (22)
SCORE (23)
Systematic
Coronary Risk Evaluation
(with risk adjustment
algorithm/tables
provided based on
population/country)
10 TC or TC/HDL-C ratio,
sex, smoking status,
systolic blood pressure
Fatal atherosclerotic event
(myocardial infarction,
stroke, occlusive arterial
disease, sudden cardiac
death)
 104,961 subjects from
7 pooled European
(Belgium, Britain,
Denmark, Finland,
Germany, Italy, Spain)
prospective studies
 Men, 55% (ages 2089 yrs)
 Women, 45%
(ages 2099 yrs)
Canadian Cardiovascular
Society (27)
Framingham Risk Score:
Global Cardiovascular
Disease Risk (29)
10 Age, sex, TC, HDL-C,
systolic blood pressure,
blood pressure
treatment, smoking
status, diabetes,
vascular age
Absolute ASCVD event
(coronary heart,
cerebrovascular,
peripheral vascular,
and heart failure)
 Framingham original and
offspring cohorts
 Men, n ¼ 3,969
 Women, n ¼ 4,522
 Ages 3074 yrs
 Caucasian
Modiﬁed Framingham Risk
Score (multiply score by
2 in presence of family
history of premature
ASCVD) (27)
American Association
of Clinical
Endocrinologists (30)
Men:
Original Framingham
Risk Score (9) Adult
Treatment Panel III
10 Sex, age, TC, HDL-C,
blood pressure, diabetes,
smoking status
Framingham Risk Score:
Myocardial infarction
and coronary heart
disease death
Framingham original and
offspring cohorts
 Men, n ¼ 2,489
 Women, n ¼ 2,856
 Ages 30–74 yrs
 Caucasian
Women:
Reynolds Risk Score
(32,33)
10 Age, systolic blood pressure,
HgbA1C if diabetic,
current smoking, TC,
HDL-C, hs-CRP, family
history premature
ASCVD
Reynolds Risk Score:
Myocardial infarction,
ischemic stroke, coronary
revascularization, and
cardiovascular death
 Women’s Health Study
 Women, n ¼ 24,558
 Ages 4859 yrs
 Caucasian ¼ 95%
 Black ¼ 1.9%
 Asian ¼ 1.4%
Kidney Disease:
Improving Global
Outcomes: Clinical
Practice Guideline for
Lipid Management
in Chronic Kidney
Disease (41)
Kidney Disease: Improving
Global Outcomes
Coronary Risk
Assessment (45)
10 Age, estimated glomerular
ﬁltration rate
Myocardial infarction or
coronary heart death
by age and estimated
glomerular ﬁltration rate
 Alberta Kidney Disease
Network
 N ¼ 1,268,029
 Women, 50%
 Mean age ¼ 49.4 yrs
Continued on the next page
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200AMERICAN ASSOCIATION OF CLINICAL ENDO-
CRINOLOGISTS. The 2012 update of the American
Association of Clinical Endocrinologists’ (AACE)
Guidelines for Management of Dyslipidemia and
Prevention of Atherosclerosis (30) were developed
according to the AACE Protocol for Standardized
Production of Clinical Practice Guidelines–2010 up-
date (31). Each recommendation is assigned an evi-
dence level based on the quality of evidence, and the
evidence is also rated for strength. The FRS (9) and
Reynolds Risk Score (32,33) are the recommended risk
assessment tools in the AACE guidelines. The latter ispreferred for CAD risk assessment in women, as the
FRS can underestimate 10-year risk in women with
2 risk factors. A fasting lipid proﬁle is the recom-
mended baseline evaluation for cardiovascular risk
detection. In the presence of elevated triglycerides
(200 to 500 mg/dl), diabetes, insulin resistance, and/
or established CAD calculation of non–HDL-C is
considered to provide more accurate risk assessment
than LDL-C alone. The AACE guidelines also recom-
mend measurement of Apo B to assess the success
of LDL-C–lowering therapy as Apo B reﬂects LDL
particle number, which may be elevated in patients at
TABLE 1 Continued
Source
Recommended Risk
Assessment Tool
Forecast
Capability of
Tool (yrs)
Risk Factors Included
for Risk Estimation
Atherosclerotic
Cardiovascular Disease
Outcome Predicted
Population Used
for Derivation/Validation
of Risk Algorithm
Effectiveness-Based
Guidelines for the
Prevention of
Cardiovascular Disease
in Women—2011
Update (37)
Framingham Risk Score:
Global Cardiovascular
Disease Risk (19)
10 Age, sex, TC, HDL-C,
systolic blood pressure,
blood pressure
treatment, smoking
status, diabetes
Framingham Risk Score:
Absolute ASCVD event
(coronary heart,
cerebrovascular,
peripheral vascular,
and heart failure)
Framingham original and
offspring cohorts
 Men, n ¼ 3,969
 Women, n ¼ 4,522
 Ages 3074 yrs
 Caucasian
Reynolds Risk Score (32,33) 10 Age, sex, systolic blood
pressure, HgbA1C
if diabetic, current
smoking, TC, HDL-C,
hs-CRP, family history
premature ASCVD
Reynolds Risk Score:
Myocardial infarction,
ischemic stroke, coronary
revascularization, and
cardiovascular death
 Women’s Health Study
 Women, n ¼ 24,558
 Ages 4859 yrs
 Caucasian ¼ 95%
 Black ¼ 1.9%
 Asian ¼ 1.4%
2013 American College of
Cardiology/American
Heart Association
Guidelines on the
Treatment of Blood
Cholesterol to Reduce
Atherosclerotic
Cardiovascular Risk
in Adults (50)
Cardiovascular Risk
Calculator based on
Pooled Cohort Risk
Equations (52)
10
Lifetime or 30
(for ages 2059
yrs)
Age, sex, ethnicity
(Caucasian or African
American), TC, HDL-C,
systolic blood pressure,
treatment for
hypertension, diabetes
Nonfatal myocardial
infarction, coronary
heart disease death,
fatal or nonfatal stroke
 Atherosclerosis Risk in
Communities
 Cardiovascular Health
Study
 Coronary Artery Risk
Development in Young
Adults
 Framingham Original and
Offspring Studies
 African American, white
men and women
 Ages 4074 yrs
ASCVD ¼ atherosclerotic cardiovascular disease; CVD ¼ cardiovascular disease; HDL-C ¼ high-density lipoprotein cholesterol; HgbA1C ¼ hemoglobin A1C; hs-CRP ¼ high-sensitivity C-reactive protein;
TC ¼ total cholesterol.
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201or below LDL-C goal. Recommended treatment goals
are similar to ATP III with the addition of optimal
Apo B levels<90mg/dl in primary prevention and<80
mg/dl in patients with established CAD or diabetes.
MANAGEMENT OF LDL-RELATED ASCVD RISK
IN SPECIAL POPULATIONS
Adding to the confusion for practitioners selecting
appropriate recommendations for the management of
LDL-related risk in individual patients is the multi-
tude of published guidelines for special populations:
children, the elderly, women, and patients with car-
diometabolic risk or diabetes, CKD, and familial
hypercholesterolemia, among others (34–40). The
unique features of these guidelines are summarized
in the Central Illustration. It is of interest to specif-
ically review the newest recommendations for man-
agement of LDL-related risk in patients with CKD,
which represent a change in the approach to lipo-
protein targets of therapy.
CHRONIC KIDNEY DISEASE. The 2013 Clinical Prac-
tice Guideline for Lipid Management in Chro-
nic Kidney Disease (41), published by the Kidney
Disease: Improving Global Outcomes (KDIGO) panel,
represents a signiﬁcant departure from the previous
guidelines of the Kidney Disease Outcomes Quality
Initiative group in 2003 (42) and 2007 (43). The inter-
national group of experts in nephrology, cardiology,epidemiology, and lipidology used the GRADE system
for evaluation of the evidence. However, the group
acknowledges that the recommendations are primar-
ily supported by a few large RCTs and post hoc ana-
lyses of the subgroup of CKD patients from statin trials
in the general population. In patients with CKD, an
initial fasting lipid proﬁle is recommended primarily
for the purpose of identiﬁcation of more severe forms
of hypercholesterolemia or hypertriglyceridemia and
to rule out remediable or secondary causes of dysli-
pidemia. However, evidence from the Alberta Kidney
Disease Network has demonstrated that in patients
with CKD who are not dependent on dialysis, the
relationship between LDL-C and ASCVD events is
weaker than in the general population (44,45). This
may possibly be related to the atherogenic dyslipide-
mia often present in CKD, which is characterized by
lower levels of LDL-C, elevated LDL particle concen-
tration, an increase in small dense LDL, reduced
HDL-C, and elevated triglycerides (44). Therefore,
according to KDIGO guidelines, the measured LDL-C
may be less useful as a marker of coronary risk
among people with advanced CKDwho are not dialysis
dependent, and it does not serve as an indication for
pharmacological treatment. Instead, therapy is guided
by the absolute risk of coronary events based on patient
age and stage of CKD or estimated glomerular ﬁltration
rate (eGFR) (45) (Table 2). The rate of coronary death or
incident MI among CKD patients age >50 years (both
TABLE 2 Rate of Coronary Death or Nonfatal Ml (by Age and eGFR)
Rate (95% CI) of Coronary Death or
Nonfatal Ml (per 1,000 Patient–Years)
Overall Male Female
Age >40 yrs (eGFR G1-G4) 14.9 (14.6–15.3) 17.4 (16.9–17.9) 12.7 (12.3–13.1)
eGFR G3a-G4 19.3 (18.8–19.8) 23.4 (22.6–24.2) 16.4 (15.8–17.0)
eGFR G1-G2 9.7 (9.3–10.0) 12.0 (11.4–12.6) 6.7 (6.3, 7.2)
Age >50 yrs (eGFR G1-G4) 17.3 (17.0–17.7) 20.2 (19.6–20.8) 14.8 (14.3–15.3)
eGFR G3a-G4 19.9 (19.4–20.4) 24.3 (23.4–25.2) 16.9 (16.3–17.5)
eGFR G1-G2 12.9 (12.4–13.4) 15.2 (14.5–16.0) 9.7 (9.0–10.5)
Age 40-50 yrs (eGFR G1-G4) 3.2 (2.9–3.6) 4.7 (4.2–5.4) 1.6 (1.2–2.0)
eGFR G3a-G4 4.7 (3.7–6.0) 5.9 (4.3–8.1) 3.6 (2.5–53)
eGFR G1-G2 3.0 (2.6–3.3) 4.6 (4.0–5.3) 1.2 (0.9–1.6)
Values are unadjusted rates from 1,268,029 participants in the Alberta Kidney Disease cohort. People with
diabetes, MI, and other cardiovascular disease were included. Data do not apply to people with Kidney
transplants. Reproduced with permission from KDIGO (41).
CI ¼ conﬁdence interval; eGFR ¼ estimated glomerular ﬁltration; MI ¼ myocardial infarction.
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202men andwomen) is consistently>10 per 1,000 patient-
years, which is considered by these experts to indicate
a potential beneﬁt of statin therapy. Speciﬁc doses of
individual statins are recommended for each stage of
CKD or eGFR, and dose titration is not indicated ac-
cording to the evidence reviewed. Statin therapy or
combination therapy with statin and ezetimibe is
not recommended in adults with dialysis-dependent
CKD due to lack of evidence of ASCVD risk reduction
in patients with stage V CKD (46–48). Epidemiologic
evidence suggests that cardiovascular events in dial-
ysis patients tend to be nonatherosclerotic and more
likely related to heart failure and arrhythmias (49).
However, therapy may be continued in patients
already receiving therapy at the time of initiation of
dialysis. The KDIGO guidelines suggest follow-up
measurement of lipid levels only when the results
would inﬂuence therapy: that is, monitoring of
adherence to statin therapy or to assess 10-year car-
diovascular disease (CVD) risk in younger CKDpatients
not currently on statin therapy. Further discussion of
this approach will follow in the review of the newest
guidelines from the ACC/American Heart Association
(AHA) on the management of blood cholesterol (50).
MANAGEMENT OF LDL-RELATED CVD RISK:
A CHANGE IN STRATEGY
In the United States, the methodology for develop-
ment of guidelines and the fundamental approach to
management of LDL-related CVD risk changed
signiﬁcantly with the publication of the 2013 ACC/
AHA Guideline on the Treatment of Blood Cholesterol
to Reduce Atherosclerotic Cardiovascular Risk in
Adults: A Report of the ACC/AHA Task Force on
Practice Guidelines in November 2013 (50). The
guideline formulation process began in 2008 when anExpert Panel of the National Heart, Lung, and Blood
Institute (NHLBI) initiated a systematic review of the
evidence and development of critical questions con-
cerning management of dyslipidemias and ASCVD
risk reduction as a foundation for publication of new
ATP IV guidelines. Therefore, unlike ATP III, the new
guidelines address only a limited number of critical
questions and do not provide comprehensive rec-
ommendations for the management of many forms of
dyslipidemia. The NHLBI subsequently initiated
collaboration with the ACC, AHA, and other sup-
porting organizations for the process of guideline
formulation, and the ﬁnal document now serves as
the most current U.S. guidelines for management of
blood cholesterol for CVD risk reduction (51).
In the 2013 ACC/AHA blood cholesterol guidelines,
the inherent differences between the evidence grading
systems of the NHLBI and the ACC/AHA required
mapping of recommendations to each format. The
NHLBI grading format includes the strength of the
recommendation and a quality rating of the strength of
the evidence. The ACC/AHA Class of Recommenda-
tion/Level of Evidence construct includes the size of
the treatment effect and an estimate of the precision or
certainty of the treatment effect. As stated in the new
guidelines, for some recommendations the alignment
between the 2 grading systems is not perfect, and ex-
planations of the variations are discussed when
present.
For primary prevention of ASCVD, the recom-
mended risk assessment tool in the ACC/AHA guide-
lines is the new CV Risk Calculator based on the
pooled cohort equations, as described in the 2013
ACC/AHA Guideline on the Assessment of Cardio-
vascular Risk (52). The equations are derived from
large, diverse, community-based cohorts that are
generally representative of the U.S. population of
whites and African Americans (53–57). The calculator
provides race- and sex-speciﬁc estimates of the 10-
year risk of ﬁrst hard ASCVD event (nonfatal myocar-
dial infarction, CHD death, fatal, or nonfatal stroke)
and should be used in non-Hispanic African Ameri-
cans and non-Hispanic whites between 40 and 79
years of age. Lifetime- or 30-year risk also is provided
for individuals age 20 to 59 years who are not at high
short-term risk. Recommended optional variables
and/or screening tests that may be considered to
reﬁne risk assessment include: family history of pre-
mature ASCVD; hs-CRP >2 mg/l; coronary artery cal-
cium score $300 Agatston units, or $75th percentile
for age, sex, and ethnicity; and ankle brachial index.
Based on expert opinion, the presence of any of these
screening abnormalities supports revising the pa-
tient’s risk assessment to a higher level of risk.
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risk assessment, the ACC/AHA guidelines also
recommend a novel strategy for management of LDL-
related risk. As discussed in the previous text,
guidelines from multiple organizations have previ-
ously focused on the fasting lipid panel as the initial
evaluation of lipid-related CVD risk. Within each
category of ASCVD risk, targets of treatment are then
speciﬁed in these recommendations. Upon systematic
review of the evidence, authors of the new ACC/AHA
guidelines determined that current clinical trial data
do not support this approach. Also, the data are
inadequate to indicate speciﬁc lipoprotein goals of
therapy. Therefore, the panel made no recommen-
dation for or against speciﬁc targets (LDL-C or non–
HDL-C) for primary or secondary ASCVD prevention.
Instead, these experts identiﬁed 4 groups of patients
in which there is the most extensive evidence of the
beneﬁt of statin therapy for prevention of ASCVD:
1. Individuals with clinical ASCVD;
2. Individuals with primary elevations of LDL-C $190
mg/dl;
3. Individuals 40 to 75 years of age with diabetes and
LDL-C 70 to 189 mg/dl; and
4. Individuals without clinical ASCVD or diabetes
who are 40 to 75 years of age with LDL-C 70 to 189
mg/dl and an estimated 10-year ASCVD risk
of $7.5% by the Pooled Risk Equations.
For each risk group, the guidelines recommend an
intensity of statin therapy, either moderate- or high-
intensity. Low-intensity statins are recommended
only in patients who have experienced or are at risk
for adverse effects of treatment. The guidelines do
not support dose titration to achieve optimal levels
of LDL-C, non–HDL-C, or Apo B, as recommended in
previous guidelines. Also, in a signiﬁcant departure
from previous guidelines, the 2013 ACC/AHA guide-
lines recommend measurement of on-therapy LDL-C
only as an assessment of adherence and response to
therapy.
GUIDELINE CONTROVERSIES
AND CONFUSIONS
It is no surprise that a revolutionary change from
decades of emphasis on LDL-C goals of therapy in
dyslipidemia would generate considerable contro-
versy and confusion among healthcare providers,
the media, and patients. It is important to note
that although there are signiﬁcant changes in
the new 2013 ACC/AHA guidelines, there are rec-
ommendations that are consistent with those of the
NCEP ATP III, ATP III update panels, and otherorganizations. LDL remains the lipoprotein of inter-
est as recommended in the previous guidelines of
the ATP III and current recommendations of the IAS,
EAS/ESC, CCS, AACE, KDIGO, the American Diabetes
Association, the National Lipid Association, and the
American Association of Pediatrics. Very high-risk
patients with manifest ASCVD or familial hypercho-
lesterolemia and/or LDL-C $190 mg/dl continue to
be candidates for high-intensity statin therapy.
Also, in patients with familial hypercholesterolemia,
combination therapy with high-intensity statins and
cholesterol absorption inhibitors, bile acid seques-
trants, LDL apheresis, or newer therapies may be
considered for additional reduction of LDL-C levels
even in the absence of a speciﬁc LDL-C target. As in
previous guidelines, the new ACC/AHA recommenda-
tions consider diabetic patients as a high-risk group;
however, the intensity of therapy is now based on
the 10-year estimate of risk of hard ASCVD event by the
pooled risk equations. Although a newly-validated risk
assessment algorithm is recommended by the ACC/
AHA in primary prevention patients and diabetics
without ASCVD, the intensity of statin therapy is still
closely related to the intensity of risk as recommended
by other guidelines. The role of assessment of other
biomarkers and noninvasive imaging for subclinical
atherosclerosis is addressed in many of the guidelines,
including the 2013 ACC/AHA, AACE, the AHA preven-
tion guidelines in women, IAS, CCS, and EAS/ESC. The
tests with the greatest incremental risk prediction
and the strongest recommendations for additional
testing beyond the standard algorithm include hs-CRP,
coronary calcium scoring, and ankle brachial index
(50). Finally, monitoring of LDL-C with follow-up
laboratory data is recommended in the 2013 ACC/
AHA guidelines as well as in other clinical practice
guidelines. However, the value is to be used only as
an assessment of compliance and response to treat-
ment rather than as a target of therapy.
The controversies and confusions that have resul-
ted with the release of the new guidelines are due to
substantive differences in both the process of guide-
line development and the content of the new ACC/
AHA clinical practice recommendations. The 2013
guidelines are narrower in scope and consider 3 crit-
ical questions in lipid management for ASCVD pre-
vention. They provide discussion of evidence but
limited recommendations for the treatment of special
populations (age <40 to >75 years; those with CKD,
HIV, inﬂammatory or rheumatolgic disorders, or pa-
tients status post solid organ transplantation; Asians,
Hispanics, or other ethnic populations) and manage-
ment of patients with complex dyslipidemias, sub-
optimal response to therapy, adverse effects on
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previous ATP III guidelines were considered to be the
reference standard for diagnosis, treatment, and
long-term follow-up of patients with the majority of
lipid disorders. It is important for providers to un-
derstand that many of the common primary preven-
tion dyslipidemia issues have not been studied in
RCTs, so the new guidelines do not provide evidence-
based recommendations for treating patients who
do not fall clearly into 1 of the 4 groups identiﬁed.
This is of particular importance in the management
of pediatric patients with LDL-related risk. Due to
ethical and practical issues in pediatric clinical
research, there are few large RCTs, and recommen-
dations must be based upon RCTs with minor limi-
tations, overwhelmingly consistent evidence from
long-term observational studies, and case control or
cohort studies (35).
The new risk assessment tool recommended in the
2013 guidelines is based on newly-derived pooled risk
equations, and concerns have been expressed re-
garding the applicability of this algorithm for the
general population and other ethnic groups and the
increased numbers of patients who qualify for mod-
erate- to high-intensity statin therapy. Application of
the new risk assessment tool in theNational Health and
Nutrition Surveys of 2005 and 2010 resulted in a sub-
stantial increase in adults eligible for statin therapy
(12.8 million), particularly in older adults (58). In a
European cohort, investigators determined that
application of the new CV Risk Calculator would
recommend that all men and 65% of women older than
age 55 years would be candidates for treatment with a
statin (59). In the study populations of the Multi-
Ethnic Study of Atherosclerosis, the Women’s Health
Study, the Physicians’ Health Study, and the Women’s
Health Initiative Observational Study, authors
compared the observed and predicted event rates by
the CV Risk Calculator, ﬁnding that the new algorithm
overestimated observed risks by approximately 75% to
150% (60). However, in the Reasons for Geographic and
Racial Differences in Stroke study, the observed and
predicted 5-year ASCVD risks were similar when pa-
tients with diabetes, LDL-C <40 or >189 mg/dl, and
current statin therapy were excluded and in Medicare
participants (61). Certainly, validation of the CV Risk
Calculator in other datasets will address these con-
cerns and determine its applicability in persons at
varying levels of ASCVD risk and in more ethnically-
diverse populations. Finally, the risk calculator also
provides 30-year or lifetime risk for patients who are
age 20 to 59 years, but the guidelines provide limited
speciﬁc information on treatment recommendations
for individuals with high lifetime risk.Probably, the most signiﬁcant and controversial
changes in the ACC/AHA recommendations are
those concerning the abandonment of lipoprotein
treatment targets and goals of therapy. Treatment is
initiated as moderate- or high-intensity statin ther-
apy, and dose titration to a speciﬁc LDL-C goal is no
longer recommended. Only patients with a high risk
of adverse events (i.e., the elderly, those with multi-
ple comorbidities, polypharmacy) are recommended
to initiate low-intensity statin therapy. Concerns
regarding the initiation of therapy with high-dose,
high-potency statin medications in ASCVD risk
reduction should be considered. Overall, adherence
to all doses of statin therapy in at-risk patients is poor
in both primary prevention and high-risk populations
(62–64). As the new AHA/ACC guidelines recommend
initiation of only high- and moderate-intensity sta-
tins in high-risk patients, there is concern for even
further reductions in compliance with prescribed
statin or appropriate statin intensity.
A number of professional societies have published
responses to the publication of these new ACC/AHA
guidelines, and some have chosen not to endorse the
recommendations based on the concerns and con-
troversies noted in the previous text, including AACE
(65) and the National Lipid Association (66). The EAS
has stated that although there are similarities be-
tween the EAS/ESC and the new ACC/AHA guidelines,
its leaders recommend no change in the approach to
LDL-related risk (67). They continue to support LDL-C
as the target of therapy and the SCORE risk assess-
ment for the European populations as detailed in the
EAS/ESC guidelines.
SUMMARY
This discussion clearly demonstrates that the number
of published guidelines for the management of LDL-
related ASCVD risk and the substantive differences
in recommendations may contribute to confusion
among providers and lead to suboptimal manage-
ment of at-risk patients. It is recommended that
professional societies work together in the future to
develop guidelines that are based on uniﬁed princi-
ples of treatment for reduction of ASCVD risk, high-
quality evidence from large RCTs, as well as other
types of research that inform us regarding mecha-
nisms of atherogenesis. In addition, a focus on spe-
cial patient populations will remain important in the
process of guideline development, as there are a
number of patients excluded from speciﬁc ACC/AHA
recommendations. Education of providers regarding
the process of guideline development and strategies
for integration of existing guidelines will be
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Clinicians and patients will beneﬁt from the under-
standing that these recommendations serve only as a
starting point for care of the individual patient.
Clinical judgment and patient preference must play
important roles in the therapeutic decision.
In the meantime, clinicians have questions re-
garding the wave of change in the new recommen-
dations and request simple tools for implementation
of guidelines into daily practice. There are also
numerous questions regarding management of pa-
tients not considered in 1 of the 4 statin beneﬁt
groups, patients with high lifetime ASCVD risk,
and patients with complex dyslipidemias. Many pa-
tients question the implications of initiation of ther-
apy with high-dose statins, the lack of speciﬁc
numeric goals of therapy, and reduced monitoringof statin therapy by laboratory assessment. Patients
require a careful explanation of the risks of dyslipi-
demia and a better understanding of the beneﬁts
of lifestyle therapy as well as the risks and bene-
ﬁts of pharmacologic strategies for management of
LDL-related risk. The ACC’s LDL: Address the Risk
program will use the information reviewed during
the Think Tank to develop more effective strategies
for clinicians to assist in the implementation of
evidence-based guidelines and for patients to
improve compliance with proven preventive lipid-
lowering therapy.
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